A significant majority of the suicide-related deaths occur in patients with major psychiatric disorders, particularly bipolar disorder (BD), major depressive disorder (MDD), and treatment-resistant depression (TRD). For example, 20% of BD subjects, most of them untreated, end their life by suicide, and a much higher percentage of them attempt suicide at least once in their lifetime.
Comorbidities of different types are also very common in patients with mood disorders (MoDs) and
the World Health Organisation International Consortium in Psychiatric Epidemiology recently
showed a significant correlation between mood disorders and substance-related disorders.
Those data alone emphasise the need for correct prevention, assessment, and treatment of such
conditions.
Mood disorders recurrence is high even when the illness is correctly diagnosed and treated, causing
severe impairments in patients’ daily lives. Nevertheless, the prediction of the course of this illness
and the anticipation of the illness onset in individuals at risk is still challenging because of the lack of reliable biomarkers with predictive validity.
Neuroimaging technology can provide useful solutions towards the identification of biomarkers for
the prevention, assessment, and treatment of mood disorders. In fact, patients' emotional profile
and cognitive impairments assessment (attention, verbal memory, executive functions) as well as
neural activity monitoring may be useful for guiding standard and novel treatments for mood
disorders.
This Research Topic aims at collecting the latest works showing the successful employment of
neuroimaging techniques and neurophysiological signals to enhance the investigation of mood
disorders. The combination of clinical standard measures and reliable biomarkers is essential to
tailor new effective treatments and assessment procedures. Broadening our knowledge of the
longitudinal course of mood symptoms and identifying neuroimaging-based measures able to
follow/predict the temporal progression of this pathological condition is cardinal for improving the
assessment and management of mood disorders. Ultimately, this research would lead to the
development of more effective prevention and early prophylactic strategies, and novel treatments.
Areas covered by this section include but are not limited to the following:
• Mood disorders prevention
• Cognitive impairments
• Mental disorders
• Psychotherapy/Online psychotherapy
• Psychoeducation
• Multimodal assessment
• Wearable technologies
• Neuroimaging
• Mood disorder assessment
All types of manuscripts are considered, including original basic science reports, translational
research, clinical studies, review articles, and methodology papers.
A significant majority of the suicide-related deaths occur in patients with major psychiatric disorders, particularly bipolar disorder (BD), major depressive disorder (MDD), and treatment-resistant depression (TRD). For example, 20% of BD subjects, most of them untreated, end their life by suicide, and a much higher percentage of them attempt suicide at least once in their lifetime.
Comorbidities of different types are also very common in patients with mood disorders (MoDs) and
the World Health Organisation International Consortium in Psychiatric Epidemiology recently
showed a significant correlation between mood disorders and substance-related disorders.
Those data alone emphasise the need for correct prevention, assessment, and treatment of such
conditions.
Mood disorders recurrence is high even when the illness is correctly diagnosed and treated, causing
severe impairments in patients’ daily lives. Nevertheless, the prediction of the course of this illness
and the anticipation of the illness onset in individuals at risk is still challenging because of the lack of reliable biomarkers with predictive validity.
Neuroimaging technology can provide useful solutions towards the identification of biomarkers for
the prevention, assessment, and treatment of mood disorders. In fact, patients' emotional profile
and cognitive impairments assessment (attention, verbal memory, executive functions) as well as
neural activity monitoring may be useful for guiding standard and novel treatments for mood
disorders.
This Research Topic aims at collecting the latest works showing the successful employment of
neuroimaging techniques and neurophysiological signals to enhance the investigation of mood
disorders. The combination of clinical standard measures and reliable biomarkers is essential to
tailor new effective treatments and assessment procedures. Broadening our knowledge of the
longitudinal course of mood symptoms and identifying neuroimaging-based measures able to
follow/predict the temporal progression of this pathological condition is cardinal for improving the
assessment and management of mood disorders. Ultimately, this research would lead to the
development of more effective prevention and early prophylactic strategies, and novel treatments.
Areas covered by this section include but are not limited to the following:
• Mood disorders prevention
• Cognitive impairments
• Mental disorders
• Psychotherapy/Online psychotherapy
• Psychoeducation
• Multimodal assessment
• Wearable technologies
• Neuroimaging
• Mood disorder assessment
All types of manuscripts are considered, including original basic science reports, translational
research, clinical studies, review articles, and methodology papers.